BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoon JH, Lee JM, Chang W, Kang HJ, Bandos A, Lim HJ, Kang SY, Kang KW, Ryoo SB, Jeong SY, Park KJ. Initial M Staging of Rectal Cancer: FDG PET/MRI with a Hepatocyte-specific Contrast Agent versus Contrast-enhanced CT. Radiology 2020;294:310-9. [PMID: 31793850 DOI: 10.1148/radiol.2019190794] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Gassert FG, Rübenthaler J, Cyran CC, Rink JS, Schwarze V, Luitjens J, Gassert FT, Makowski MR, Schoenberg SO, Mayerhoefer ME, Tamandl D, Froelich MF. 18F FDG PET/MRI with hepatocyte-specific contrast agent for M staging of rectal cancer: a primary economic evaluation. Eur J Nucl Med Mol Imaging 2021. [PMID: 33686457 DOI: 10.1007/s00259-021-05193-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Moradi F, Iagaru A, McConathy J. Clinical Applications of PET/MR Imaging. Radiol Clin North Am 2021;59:853-74. [PMID: 34392923 DOI: 10.1016/j.rcl.2021.05.013] [Reference Citation Analysis]
3 Crimì F, Valeggia S, Baffoni L, Stramare R, Lacognata C, Spolverato G, Albertoni L, Spimpolo A, Evangelista L, Zucchetta P, Cecchin D, Pucciarelli S. [18F]FDG PET/MRI in rectal cancer. Ann Nucl Med 2021;35:281-90. [PMID: 33517562 DOI: 10.1007/s12149-021-01580-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Pirasteh A, Lovrec P, Pedrosa I. Imaging and its Impact on Defining the Oligometastatic State. Semin Radiat Oncol 2021;31:186-99. [PMID: 34090645 DOI: 10.1016/j.semradonc.2021.03.006] [Reference Citation Analysis]
5 Vermersch M, Mulé S, Chalaye J, Galletto Pregliasco A, Emsen B, Amaddeo G, Monnet A, Stemmer A, Baranes L, Laurent A, Leroy V, Itti E, Luciani A. Impact of the 18F-FDG-PET/MRI on Metastatic Staging in Patients with Hepatocellular Carcinoma: Initial Results from 104 Patients. J Clin Med 2021;10:4017. [PMID: 34501465 DOI: 10.3390/jcm10174017] [Reference Citation Analysis]
6 Li Y, Mueller LI, Neuhaus JP, Bertram S, Schaarschmidt BM, Demircioglu A, Ludwig JM, Kirchner J, Rischpler C, Herrmann K, Catalano OA, Umutlu L. 18F-FDG PET/MR versus MR Alone in Whole-Body Primary Staging and Restaging of Patients with Rectal Cancer: What Is the Benefit of PET? J Clin Med 2020;9:E3163. [PMID: 33003615 DOI: 10.3390/jcm9103163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Galgano SJ, Calderone CE, Xie C, Smith EN, Porter KK, McConathy JE. Applications of PET/MRI in Abdominopelvic Oncology. Radiographics 2021;41:1750-65. [PMID: 34597228 DOI: 10.1148/rg.2021210035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yoon JH, Yu MH, Hur BY, Park CM, Lee JM. Detection of distant metastases in rectal cancer: contrast-enhanced CT vs whole body MRI. Eur Radiol 2021;31:104-11. [PMID: 32789755 DOI: 10.1007/s00330-020-07149-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Queiroz MA, Ortega CD, Ferreira FR, Capareli FC, Nahas SC, Cerri GG, Buchpiguel CA. Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease. Mol Imaging Biol 2021. [PMID: 34755248 DOI: 10.1007/s11307-021-01674-1] [Reference Citation Analysis]